Signaturefd LLC Cuts Stock Position in GSK plc (NYSE:GSK)

Signaturefd LLC lessened its position in shares of GSK plc (NYSE:GSK) by 5.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,055 shares of the pharmaceutical company’s stock after selling 1,705 shares during the quarter. Signaturefd LLC’s holdings in GSK were worth $1,310,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GSK. JTC Employer Solutions Trustee Ltd lifted its holdings in shares of GSK by 71.3% during the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after purchasing an additional 8,800,822 shares during the last quarter. Primecap Management Co. CA raised its stake in GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after buying an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD boosted its holdings in GSK by 37.8% in the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after acquiring an additional 1,512,442 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of GSK by 180.0% during the first quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock worth $95,129,000 after acquiring an additional 1,426,935 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK during the second quarter valued at about $52,487,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

NYSE:GSK opened at $37.96 on Thursday. The firm’s fifty day moving average is $41.27 and its two-hundred day moving average is $41.19. The firm has a market cap of $78.67 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. GSK plc has a one year low of $33.67 and a one year high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 4.05%. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Insider Activity

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Jefferies Financial Group boosted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, GSK presently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.